Abstracts Archive - Page 2110 of 2607 - ACR Meeting Abstracts

Abstract Number: 1861 • 2014 ACR/ARHP Annual Meeting
The Role of Macrophage Migration Inhibitory Factor (MIF) and MIF Gene Polymorphisms in the Pathogenesis of Granulomatosis with Polyangiitis
Antoine G. Sreih¹, Rana Ezzeddine², Juan Fan³, Lin Leng³, Simon Carette⁴, David Cuthbertson⁵, Gary S. Hoffman⁶, Nader A. Khalidi⁷, Carol A. Langford⁸, Carol McAlear⁹, Paul Monach¹⁰, Philip Seo¹¹, Ulrich Specks¹², Steven R. Ytterberg¹³, Peter A. Merkel¹⁴ and Richard Bucala¹⁵, ¹Medicine/Division of Rheumatology, The University of Pennsylvania, Philadelphia, PA, ²Biostatistics, Bristol-Myers Squibb, Wallingford, CT, ³Yale University, New Haven, CT, ⁴Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵Department of Biostatistics, University of South Florida, Tampa, FL, ⁶Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁷Division of Rheumatology, St. Joseph’s Hospital, McMaster University, Hamilton, ON, Canada, ⁸Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁹Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ¹⁰Rheumatology, Boston University, Boston, MA, ¹¹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹²Frederichs Dr NW, Mayo Clinic, Rochester, MN, ¹³Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹⁴Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁵Rheum/Dept of Int Med, Yale University School of Med, New Haven, CT
Background/Purpose: Macrophage Migration Inhibitory Factor (MIF) is an immunoregulatory cytokine that may play a central role in the pathogenesis of granulomatous diseases. Two functional polymorphisms…
Abstract Number: 1860 • 2014 ACR/ARHP Annual Meeting
Serum Calprotectin and Disease Relapse in ANCA-Associated Vasculitis
Juliana B Draibe¹, Ruth J. Pepper¹, Peter A. Merkel², Alan D. Salama¹ and for The RAVE-ITN Investigators³, ¹Centre for Nephrology, University College London, London, United Kingdom, ²University of Pennsylvania, Philadelphia, PA, ³Immune Tolerance Network, San Franciscco, CA
Background/Purpose: In ANCA-associated vasculitis (AAV) disease relapses remain common but there are no reliable means to predict them. We previously demonstrated that serum calprotectin…
Abstract Number: 1859 • 2014 ACR/ARHP Annual Meeting
Age-Specific Predictors of Mortality in SLE
Dominique Ibanez¹, Dafna D. Gladman² and Murray B. Urowitz², ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Mortality is 3 to 5 times greater in SLE patients then it is in the general population – especially among younger patients where it…
Abstract Number: 1858 • 2014 ACR/ARHP Annual Meeting
Standardized Mortality Ratios for Cause-Specific Deaths in Lupus Patients Followed Prospectively at a Single Centre Lupus Clinic
Barry J. Sheane¹, Dominique Ibanez², Dafna D. Gladman³ and Murray B. Urowitz³, ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose Despite the significant improvement in survival rates of patients with systemic lupus erythematosus (SLE) over the last four decades, mortality rates have remained at…
Abstract Number: 1856 • 2014 ACR/ARHP Annual Meeting
National Hospitalization Trends in Lupus Reveal Rising Rates of Herpes Zoster and Declines in Pneumocystis Infections
Sara G. Murray¹, Gabriela Schmajuk¹, Laura Trupin¹, Lianne S. Gensler² and Jinoos Yazdany¹, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Infection is a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). With changing therapeutic practices over the past 15 years,…
Abstract Number: 1855 • 2014 ACR/ARHP Annual Meeting
Not Keeping up with the Times: High Mortality and Early Death Due to Disease in North American Natives with Systemic Lupus Erythematosus (SLE)
Ripneet Puar¹, Carol A. Hitchon², David B. Robinson³, Hani El-Gabalawy³, Navjot Dhindsa¹ and Christine A. Peschken⁴, ¹Medicine, University of Manitoba, Winnipeg, MB, Canada, ²Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ³Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, ⁴University of Manitoba, Canada, Winnipeg, MB, Canada
Background/Purpose: Reports in recent decades show drastic improvements in survival of SLE patients, with 10-15 year survival rates of >90%. However, little is known about…
Abstract Number: 1854 • 2014 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Patients Have Increased Risk of Short Term Adverse Events after Total Hip Arthroplasty
Jordan Roberts¹, Lisa A. Mandl², Edwin Su³, David J. Mayman⁴, Mark P. Figgie⁴, Arielle Fein⁵, Yuo-Yu Lee⁵, Ummara Shah⁶ and Susan M. Goodman², ¹Weill Cornell Medical College, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Orthopedic Surgery, Hospital for Special Surgery, New York, NY, ⁴Orthopedics, Hospital for Special Surgery, New York, NY, ⁵Hospital for Special Surgery, New York, NY, ⁶Division of Rheumatology, New York University School of Medicine, NYC, NY
Background/Purpose: Total Hip Arthroplasty (THA) is the most frequent orthopedic procedure performed in lupus (SLE) patients. Whether SLE patients have higher rates of complications after…
Abstract Number: 1852 • 2014 ACR/ARHP Annual Meeting
Increased Cardiovascular Risk in Patients Recently Diagnosed with Psoriatic Arthritis: A Population-Based, Cohort Study
Katelynn Wilton¹, Floranne C. Ernste², Cynthia S. Crowson³, Eric L. Matteson⁴, Hilal Maradit Kremers⁵ and Marta Sánchez-Menéndez⁶, ¹Medical Scientist Training Program, Mayo Clinic Rochester, Rochester, MN, ²Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Health Sciences Research, Mayo Clinic, Rochester, MN, ⁶Centro Medico de Asturias, Oviedo, Spain
Background/Purpose: Patients diagnosed with rheumatoid arthritis and psoriatic arthritis (PsA) have an increased risk of multiple comorbidities that predispose them to cardiovascular disease (CVD). Although…
Abstract Number: 1851 • 2014 ACR/ARHP Annual Meeting
Serious Infection Events in the Psoriasis Longitudinal Assessment and Registry Study: Cumulative Experience
Robert Kalb¹, David Fiorentino², Mark Lebwohl³, Craig Leonardi⁴, John Toole⁵, Kavitha Goyal⁶, Steve Calabro⁶, Wayne Langholff⁷ and Steve Fakharzadeh⁸, ¹SUNY at Buffalo, School of Medicine and Biological Sciences, Buffalo, NY, ²Dermatology, Stanford University, Redwood City, CA, ³Mount Sinai Medical Center, New York, NY, ⁴Central Dermatology, St. Louis, MO, ⁵University of Manitoba, Dermadvances Research, Winnipeg, MB, Canada, ⁶Janssen Services, LLC, Horsham, PA, ⁷Janssen Research and Development, LLC, Spring House, PA, ⁸Janssen Services, LLC, Spring House, PA
Background/Purpose To report the cumulative rates of serious infections in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) study. Methods PSOLAR is a multicenter, longitudinal, observational…
Abstract Number: 1866 • 2014 ACR/ARHP Annual Meeting
Birth Outcomes in Women with a History of Juvenile Idiopathic Arthritis
Debbie Ehrmann Feldman¹, Evelyne Vinet², Sasha Bernatsky³, Ciaran Duffy⁴, Elizabeth Hazel⁵, Marie-Pierre Sylvestre⁶, Garbis Meshefedjian⁷ and Anick Bérard¹, ¹Université de Montréal, Montréal, QC, Canada, ²McGill University Health Center, Montreal, QC, Canada, ³Clinical Epidemiology - Rheumatology, McGill University, Montreal, QC, Canada, ⁴Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ⁵McGill University Heatlh Center, Montreal, QC, Canada, ⁶médecine sociale et préventive, Université de Montréal, Montréal, QC, Canada, ⁷Public Health Department of Montreal, Montreal, QC, Canada
Background/Purpose: Although there is a higher frequency of adverse birth outcomes in women with rheumatoid arthritis, little is known on the subject regarding women who…
Abstract Number: 1865 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Myocardial Infarction and Cerebrovascular Accidents after Diagnosis of Granulomatosis with Polyangiitis: A General Population-Based Cohort Study
Neda Amiri¹, Natasha Dehghan², Eric C. Sayre³, Kamran Shojania¹ and J. Antonio Avina-Zubieta⁴, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose Limited literature is available on the incidence of myocardial infarction (MI) and cerebrovascular accidents (CVA) in patients with Granulomatosis with Polyangiitis (GPA). We assessed…
Abstract Number: 1864 • 2014 ACR/ARHP Annual Meeting
Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Long-Term Outcomes of the Prospective Wegent Trial Comparing Azathioprine Vs Methotrexate for Remission-Maintenance in 126 Patients
Xavier Puéchal¹, Christian Pagnoux², Elodie Perrodeau³, Mohamed Hamidou⁴, Jean-Jacques Boffa⁵, Xavier Kyndt⁶, François Lifermann⁷, Thomas Papo⁸, Dominique Merrien⁹, Amar Smail¹⁰, Philippe Delaval¹¹, Catherine Hanrotel-Saliou¹², Bernard Imbert¹³, Chahéra Khouatra¹⁴, Marc Lambert¹⁵, Charles Leské¹⁶, Kim Heang Ly¹⁷, Edouard Pertuiset¹⁸, Pascal Roblot¹⁹, Marc Ruivard²⁰, Jean-François Subra²¹, Jean-Francois Viallard²², Benjamin Terrier¹, Pascal Cohen¹, Luc Mouthon¹, Philippe Ravaud³ and Loïc Guillevin for the French Vasculitis Study Group¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ²Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ³Epidemiology, Université Paris-Descartes, Paris, Paris, France, ⁴CHU Hôtel Dieu, Nantes, Nantes, France, ⁵Hôpital Tenon, Paris, Paris, France, ⁶Department of Nephrology and Internal Medicine, CH, Valenciennes, Valenciennes, France, ⁷Internal Medicine, CH Côte d'Argent, Dax, Dax, France, ⁸Internal Medicine, Bichat Hospital, Paris, Paris, France, ⁹CH Compiègne-Noyon, Compiègne, France, ¹⁰Internal Medicine Department, CHU Amiens Nord, Amiens, France, ¹¹CHU Rennes Sud, Rennes, France, ¹²CHU Cavale Blanche, Brest, Brest, France, ¹³CHU, Grenoble, Grenoble, France, ¹⁴CHU Louis Pradel, Lyon, Lyon, France, ¹⁵Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ¹⁶CH, Cholet, Cholet, France, ¹⁷CHU Dupuytren, Limoges, Limoges, France, ¹⁸Rheumatology, René Dubos Hospital, Pontoise, France, ¹⁹CHU, Poitiers, Poitiers, France, ²⁰CHU Estaing, Clermont–Ferrand, Clermont–Ferrand, France, ²¹CHU, Angers, Angers, France, ²²Hôpital Haut-Lévêque, Bordeaux, CHU Bordeaux, France
Background/Purpose Results of the previously reported randomized–controlled WEGENT trial demonstrated that, at 28 months, methotrexate (MTX) is as effective as azathioprine (AZA) for maintaining remission…
Abstract Number: 1853 • 2014 ACR/ARHP Annual Meeting
Persistence and Predictors of Biologic TNFi Therapy Among Biologic naïve Psoriatic Arthritis Patients in a US Registry
Philip J. Mease¹, David Collier², Chitra Karki³, Guo Li⁴, Bojena Bitman⁵ and Jeffrey D. Greenberg^3,6, ¹Director, Rheumatology Research, Swedish Medical Center, Seattle, WA, ²Amgen, Inc., Thousand Oaks, CA, ³Corrona, LLC., Southborough, MA, ⁴Axio Research LLC, Seattle, WA, ⁵Amgen, Inc., San Francisco, CA, ⁶Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Registry data regarding biologic DMARD therapy as a mono or combo (combined with a traditional oral DMARD) in subjects with Psoriatic Arthritis (PsA) are…
Abstract Number: 1857 • 2014 ACR/ARHP Annual Meeting
Determinants of Annual Healthcare Utilization and Overall Cost of Care in Individuals with Systemic Lupus Erythematosus in a Large Insurance Claims Database: Glucocorticoid Use
Shih-Yin Chen¹, Chan-Bum Choi^2,3,4, Qian Li⁵, Wei-Shi Yeh¹, Yuan-Chi Lee⁶, Amy H Kao¹ and Matthew H. Liang⁷, ¹Biogen Idec, Cambridge, MA, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Section of Rheumatology, VA Healthcare System, Boston, MA, ⁴Department of Aging, Brigham and Women's Hospital, Boston, MA, ⁵Evidera, Lexington, MA, ⁶Formerly of Evidera, Lexington, MA, ⁷Harvard Medical School, Boston, MA
Background/Purpose: Newer therapeutic agents in systemic lupus erythematosus (SLE) may increase cost of care but their effect on limiting the duration and the dosage of…
Abstract Number: 1839 • 2014 ACR/ARHP Annual Meeting
Risk of Recurrent Non-Melanoma Skin Cancer with Methotrexate and Anti-TNF Use in Rheumatoid Arthritis
Frank I Scott¹, Ronac Mamtani¹, Colleen Brensinger¹, Kevin Haynes², Zelma ChiesaFuxench¹, Huifeng Yun³, Jie Zhang⁴, Lang Chen⁵, Fenglong Xie⁶, David Margolis⁷, James D. Lewis² and Jeffrey R. Curtis⁸, ¹University of Pennsylvania, Philadelphia, PA, ²Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ³Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁴Ryals Soph Bldg., Rm. 517b, Univ. of Alabama at Birmingham, Birmingham, AL, ⁵Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁷Dermatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁸The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) and anti-TNF drugs have been hypothesized to increase the risk of a first non-melanoma skin cancer (NMSC). Among patients with prior NMSC,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].